Antiphospholipid Syndrome: Sydney Criteria, Triple Positivity, and Warfarin over DOAC Strategy
Diagnostic algorithm, risk stratification by antibody profile, anticoagulation choice, and CAPS management per ACR/EULAR 2019.
Executive Summary
Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia defined by recurrent vascular thrombosis or pregnancy morbidity in the presence of persistent antiphospholipid antibodies. The 2006 revised Sapporo (Sydney) classification criteria require one clinical event (vascular thrombosis or pregnancy morbidity) plus one positive laboratory criterion — lupus anticoagulant (LA), anticardiolipin (aCL) IgG or IgM at medium-to-high titer (>40 GPL or MPL or >99th percentile), or anti-β2 glycoprotein I (anti-β2GPI) IgG or IgM at >99th percentile — confirmed twice at ≥12-week intervals. APS occurs in 0.05 percent of the general population, but antiphospholipid antibodies are present in 30 to 40 percent of SLE patients and 10 to 20 percent of CTEPH cohorts. Risk stratification is dominated by triple positivity (LA + aCL + anti-β2GPI) which carries 4 to 6 percent annual thrombotic recurrence on warfarin. Cornerstone management is lifelong vitamin K antagonist anticoagulation: warfarin INR 2 to 3 for first venous thrombosis, INR 3 to 4 (or add aspirin) for arterial thrombosis or recurrence on therapeutic INR. DOACs are NOT recommended after the TRAPS trial demonstrated excess arterial events with rivaroxaban in triple-positive APS. Hydroxychloroquine reduces antibody titers and thrombotic risk, especially in SLE-APS. Catastrophic APS (CAPS) is a fulminant multi-organ thrombotic microangiopathy with 30 to 50 percent mortality, treated with triple therapy: anticoagulation + glucocorticoids + IVIG or plasma exchange. Obstetric APS requires prophylactic LMWH plus low-dose aspirin throughout pregnancy.
S1. Pathophysiology and Clinical Spectrum
APS is an acquired autoimmune thrombophilia in which IgG, IgM, and IgA autoantibodies target phospholipid-binding plasma proteins, primarily β2 glycoprotein I (β2GPI), prothrombin, and anionic phospholipids. The dominant pathogenic antibody is anti-β2GPI IgG directed at domain I of β2GPI, which after binding triggers endothelial activation, platelet activation through GPIbα and apolipoprotein E receptor 2 (apoER2), monocyte tissue factor expression, complement activation through C5a and the membrane attack complex, and inhibition of fibrinolysis through suppression of annexin A5 anticoagulant shield. The two-hit hypothesis posits that antibody presence alone is insufficient and that a second insult (infection, trauma, pregnancy, surgery, immobilization, smoking, estrogen) triggers thrombosis on a primed endothelial-platelet surface.
Clinical phenotypes
APS manifests across three broad phenotypes: vascular thrombosis (venous, arterial, microvascular), obstetric morbidity (recurrent miscarriage, fetal death, preeclampsia, IUGR), and non-criteria manifestations (livedo reticularis, livedoid vasculopathy, thrombocytopenia, hemolytic anemia, valvular heart disease, cognitive dysfunction, nephropathy, transverse myelitis). Venous thromboembolism (DVT, PE) is the most common presentation (~32 percent), followed by stroke (~13 percent) and TIA (~7 percent). Cerebral venous sinus thrombosis, retinal vein occlusion, hepatic vein thrombosis (Budd-Chiari), portal vein thrombosis, and adrenal vein thrombosis (Addisonian crisis) all occur disproportionately in APS.
| Phenotype | Manifestations | Prevalence in APS |
|---|---|---|
| Venous thrombosis | DVT, PE, cerebral venous sinus thrombosis, hepatic vein, portal vein, adrenal vein, retinal vein | ~32% |
| Arterial thrombosis | Stroke (13%), TIA (7%), myocardial infarction, peripheral arterial occlusion, mesenteric ischemia | ~25% |
| Obstetric morbidity | Recurrent miscarriage <10 wk, fetal death ≥10 wk, preeclampsia, IUGR, placental insufficiency | ~15% |
| Microvascular / non-criteria | Livedo reticularis (24%), livedoid vasculopathy, thrombocytopenia (20%), hemolytic anemia, Libman-Sacks endocarditis, APS nephropathy, cognitive dysfunction | 20–30% |
| Catastrophic APS (CAPS) | Multi-organ failure (≥3 organs in <1 week), small-vessel TMA, often triggered by infection | ~1% |
Recognize the unusual thrombosis
Suspect APS when a young patient (<50 years) presents with thrombosis at unusual sites — cerebral venous sinus, hepatic vein (Budd-Chiari), portal vein, mesenteric vein, retinal vein, adrenal vein — or with arterial events without conventional atherosclerotic risk factors, recurrent thrombosis on adequate anticoagulation, livedo reticularis with stroke (Sneddon syndrome), or unexplained recurrent miscarriage. Order LA + aCL + anti-β2GPI as a panel, never alone.
S2. Sydney Classification Criteria and aPL Testing
The 2006 revised Sapporo (Sydney) classification criteria require AT LEAST ONE clinical criterion AND AT LEAST ONE laboratory criterion, with the laboratory abnormality confirmed at two time points separated by at least 12 weeks. The 2023 ACR/EULAR criteria refine these with weighted scoring but the Sydney framework remains in widespread clinical use.
Clinical criteria (one or more)
- Vascular thrombosis: one or more episodes of arterial, venous, or small-vessel thrombosis in any tissue or organ, objectively confirmed by imaging or histopathology (without underlying inflammation in the vessel wall).
- Pregnancy morbidity: (a) one or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week, OR (b) one or more premature births of a morphologically normal neonate before 34 weeks because of eclampsia, severe preeclampsia, or recognized placental insufficiency, OR (c) three or more unexplained consecutive spontaneous abortions before the 10th week (with maternal anatomic, hormonal, and parental chromosomal causes excluded).
Laboratory criteria (one or more, on two occasions ≥12 weeks apart)
| Test | Method | Positive Threshold | Notes |
|---|---|---|---|
| Lupus anticoagulant (LA) | Functional clotting assay (DRVVT, aPTT-LA) | Per ISTH 3-step protocol: prolonged screen, mixing study fails to correct, phospholipid-dependent confirmation | Most specific; falsely positive with anticoagulants — interpret carefully |
| Anticardiolipin (aCL) IgG / IgM | Standardized ELISA | >40 GPL or MPL units OR >99th percentile | IgG more thrombogenic than IgM |
| Anti-β2 glycoprotein I (anti-β2GPI) IgG / IgM | Standardized ELISA | >99th percentile | Anti-domain I most pathogenic subset |
| Non-criteria antibodies (research) | Anti-phosphatidylserine, anti-prothrombin, anti-PS/PT, IgA isotypes | — | Not in Sydney criteria but raise suspicion when single criteria positive |
Lupus anticoagulant testing pitfalls
LA testing is the most reliable predictor of thrombotic risk but is technically difficult. Anticoagulants confound interpretation: warfarin prolongs aPTT-based assays causing false positives or negatives; rivaroxaban and apixaban interfere with DRVVT and silica clotting time. Test LA off anticoagulation when possible, or use alternative assays (Taipan or Ecarin time) on rivaroxaban. Repeat all positive aPL tests at 12 weeks because transient antibodies (post-infection, post-medication) do not satisfy criteria.
Triple positivity and risk stratification
Patients positive for ALL THREE laboratory criteria (LA + aCL + anti-β2GPI) have the highest thrombotic risk: 4 to 6 percent annual recurrence on adequate warfarin. Single-positive low-titer patients (low aCL or anti-β2GPI alone) have substantially lower risk and may not require lifelong anticoagulation after a provoked event. The high-risk profile defines management intensity.
| Antibody Profile | Annual Thrombotic Risk | Treatment Intensity |
|---|---|---|
| Triple positive (LA + aCL + anti-β2GPI) | 4–6% on warfarin INR 2–3 | Lifelong warfarin INR 2–3 (venous) or 3–4 (arterial); NO DOAC |
| Double positive (any 2) | 2–3% on warfarin | Lifelong warfarin INR 2–3 |
| LA alone (persistent high-titer) | 3–5% on warfarin | Lifelong warfarin INR 2–3 |
| Single low-titer aCL or anti-β2GPI | ~1% (close to general) | Anticoagulation duration based on event provocation; consider stopping at 6–12 mo if provoked event |
S3. Diagnostic Algorithm and Differential
Differential diagnosis
The differential for unusual-site thrombosis includes inherited thrombophilias (factor V Leiden, prothrombin G20210A, protein C / S / antithrombin deficiency, hyperhomocysteinemia), myeloproliferative neoplasms (especially JAK2 V617F-positive, often presenting with hepatic or portal vein thrombosis), paroxysmal nocturnal hemoglobinuria (PNH), heparin-induced thrombocytopenia (HIT), nephrotic syndrome, malignancy, hormonal therapy, and immobility. Order CBC with smear, JAK2 V617F (if splanchnic vein thrombosis), flow cytometry for PNH, factor V Leiden / prothrombin gene testing, antithrombin / protein C / protein S levels (off anticoagulation), and SLE workup (ANA, anti-dsDNA, complement) in any suspected APS workup.
Adjunctive findings supporting APS
- Prolonged aPTT not corrected by mixing study (LA effect)
- Thrombocytopenia (mild, 100–150 × 10⁹/L; severe in CAPS)
- Hemolytic anemia with positive direct antiglobulin test
- Livedo reticularis or livedo racemosa
- Libman-Sacks vegetations on echocardiography (sterile mitral or aortic valve thickening)
- APS nephropathy on biopsy (small-vessel TMA, fibrous intimal hyperplasia, focal cortical atrophy)
- White matter lesions on brain MRI in young stroke
S4. Anticoagulation: Warfarin vs DOAC and INR Targets
Initial and long-term anticoagulation
For acute venous or arterial thrombosis with confirmed APS, initial parenteral anticoagulation (LMWH or UFH) is bridged to vitamin K antagonist warfarin with target INR 2 to 3 for venous events. Therapy is lifelong because of high recurrence risk. For arterial thrombosis or recurrent thrombosis on therapeutic INR 2–3, intensify to INR 3 to 4 OR add low-dose aspirin 81 mg daily to standard-intensity warfarin (the latter approach is favored by some experts to limit bleeding).
| Indication | Anticoagulation | Duration | INR Target |
|---|---|---|---|
| First venous thrombosis (DVT/PE) | Warfarin | Lifelong | 2.0–3.0 |
| Arterial thrombosis (stroke, MI) | Warfarin OR Warfarin + ASA 81 mg | Lifelong | 2.0–3.0 (with ASA) or 3.0–4.0 (alone) |
| Recurrent thrombosis on therapeutic INR | Intensify warfarin OR add ASA OR switch to LMWH | Lifelong | 3.0–4.0 (or LMWH-equivalent) |
| Mechanical heart valve + APS | Warfarin only | Lifelong | 2.5–3.5 (per valve type) |
| Asymptomatic high-risk aPL (triple+, SLE) | Low-dose aspirin 81 mg + HCQ if SLE | Indefinite | — |
| Asymptomatic low-risk aPL (single low-titer) | Cardiovascular risk modification only | — | — |
Why DOACs are not first-line in APS
The TRAPS (Trial on Rivaroxaban in AntiPhospholipid Syndrome) randomized 120 triple-positive APS patients to rivaroxaban 20 mg daily versus warfarin INR 2–3. The trial was halted early after a significant excess of arterial events in the rivaroxaban arm: 12 percent versus 0 percent at median 19 months follow-up, with no DOAC patients suffering venous events but several myocardial infarctions and strokes. RAPS (Rivaroxaban in APS, lower-risk cohort) showed equivalence for venous events but did not assess arterial outcomes adequately. ASTRO-APS (apixaban) was halted for futility. EULAR 2019 recommends warfarin first-line for ALL APS regardless of antibody profile. DOACs may be considered ONLY if warfarin is not feasible (extreme INR variability, allergy, intolerance) AND triple positivity has been excluded AND after explicit risk discussion with the patient.
NEVER use DOAC in triple-positive APS
Triple positivity (LA + aCL + anti-β2GPI) is an absolute indication for warfarin. DOACs increase arterial thrombotic risk in this population per TRAPS. Patients on DOAC at presentation with newly diagnosed triple-positive APS should be transitioned to warfarin promptly. If an APS patient on DOAC has a breakthrough event, switch to warfarin immediately, intensify INR target, and consider adding aspirin or hydroxychloroquine.
Adjunctive therapy
- Hydroxychloroquine 200–400 mg PO daily reduces antibody titers, improves microvascular thrombosis, and is recommended in all SLE-associated APS and considered in primary APS.
- Statin therapy reduces inflammatory markers and tissue factor expression; consider in all APS patients with cardiovascular risk.
- Low-dose aspirin 81 mg PO daily for primary prevention in high-risk asymptomatic carriers (triple+, SLE-APS).
- Avoid estrogen-containing contraceptives in any APS or persistent aPL carrier — substitute progestin-only methods, IUDs, or barrier methods.
Pearl
The lupus anticoagulant test is the strongest single predictor of thrombosis. When all three antibodies (LA, aCL, anti-β2GPI) are positive at high titer (triple positive), annual recurrence on warfarin INR 2–3 still reaches 4 to 6 percent — these patients merit aggressive risk modification, hydroxychloroquine addition, statin therapy, and counseling about lifelong therapy. The presence of LA alone (with negative aCL and anti-β2GPI) confers similar risk and similarly mandates lifelong VKA.
Pitfall
Stopping anticoagulation in APS after 6 to 12 months of "provoked" thrombosis is a common error. APS is itself an UNPROVOKED prothrombotic state; the "provoking" surgery or immobilization is merely the second hit on a primed system. Recurrence within 1 year of warfarin discontinuation in confirmed APS exceeds 50 percent. Lifelong therapy is the standard. Re-discuss this principle at every visit; patients often want to stop anticoagulation and need ongoing reinforcement.
S5. Catastrophic APS (CAPS) Management
Catastrophic antiphospholipid syndrome (CAPS) is a fulminant, often fatal multi-organ thrombotic microangiopathy occurring in approximately 1 percent of APS patients. It is defined by simultaneous involvement of three or more organs developing within less than one week, evidence of small-vessel occlusion confirmed by imaging or histopathology, and laboratory confirmation of antiphospholipid antibodies (often without prior known APS). Triggers include infection (~50 percent of cases), surgery, anticoagulation withdrawal, malignancy, lupus flare, or pregnancy. Mortality remains 30 to 50 percent despite aggressive management.
CAPS classification criteria (preliminary)
- Evidence of involvement of three or more organs, systems, or tissues
- Development of manifestations simultaneously or within less than one week
- Confirmation by histopathology of small-vessel occlusion in at least one organ or tissue
- Laboratory confirmation of antiphospholipid antibodies (usually high titer)
Definite CAPS = all four criteria. Probable CAPS = three of four with specific exceptions allowed.
Triple therapy (CAPS Registry consensus)
| Component | Regimen | Rationale |
|---|---|---|
| 1. Anticoagulation | UFH IV 80 units/kg bolus → 18 units/kg/h, target aPTT 1.5–2.5× | Block ongoing thrombosis; transition to warfarin INR 3–4 once stable |
| 2. Glucocorticoids | Methylprednisolone 1 g IV daily × 3 days → prednisone 1 mg/kg/day taper | Suppress cytokine storm and complement activation |
| 3a. IVIG | 0.4 g/kg/day IV × 5 days | Neutralize aPL, immunomodulate |
| 3b. Plasma exchange (alternative or additional) | 1.0–1.5 plasma volumes daily × 3–5 sessions, replace with FFP | Remove circulating aPL and cytokines |
| Rescue (refractory) | Rituximab 375 mg/m² IV weekly × 4 OR Eculizumab 900 mg IV weekly × 4 → 1200 mg q2 weeks | Rituximab depletes aPL-producing B cells; eculizumab blocks terminal complement |
Supportive care
ICU admission with multi-organ support: mechanical ventilation for ARDS, renal replacement therapy for AKI, vasopressors for shock, source control for any infectious trigger (broad-spectrum antibiotics empirically). Treat underlying lupus flare with additional immunosuppression. Avoid procedures and minimize line manipulation to limit further thrombotic stimulus. Cyclophosphamide 0.5 to 1 g/m² IV monthly is added if SLE-CAPS overlap. Once stable, transition to lifelong warfarin INR 3 to 4 plus hydroxychloroquine plus aspirin.
CAPS triggered by anticoagulation withdrawal
One of the most preventable CAPS triggers is intentional anticoagulation interruption — for surgery, dental procedures, INR fluctuation, or patient-driven discontinuation. Use the shortest possible interruption with bridging LMWH for any procedure. Re-engage warfarin within 24 hours postoperatively. Educate patients that even a brief interruption can precipitate catastrophic APS. CAPS Registry shows ~6 percent of cases follow elective anticoagulation interruption.
S6. Obstetric APS, SLE-APS, and Special Populations
Obstetric APS
Obstetric APS is defined by recurrent miscarriage, fetal death, or premature birth from placental insufficiency in the presence of persistent aPL antibodies. Pathogenesis involves antibody-mediated trophoblast injury, complement activation, and uteroplacental small-vessel thrombosis. Without treatment, live-birth rates are 20 to 30 percent. With combined therapy (low-dose aspirin + LMWH), live-birth rates rise to 70 to 80 percent.
| Patient Profile | Antepartum Therapy | Postpartum Therapy |
|---|---|---|
| aPL+ no clinical events, no prior pregnancy loss | Low-dose aspirin 81 mg daily | Low-dose aspirin continued |
| Obstetric APS (no thrombosis history) | ASA 81 mg daily + Enoxaparin 40 mg SC daily | Continue LMWH × 6 weeks postpartum |
| Thrombotic APS (prior thrombosis) | ASA 81 mg + Enoxaparin 1 mg/kg SC q12h (therapeutic LMWH; convert from warfarin pre-conception) | Resume warfarin postpartum (compatible with breastfeeding) |
| Refractory recurrent loss despite ASA + LMWH | Add hydroxychloroquine 200–400 mg daily; consider IVIG 0.4 g/kg/mo or low-dose prednisone in T1 | Continue HCQ; reassess |
Warfarin teratogenicity: warfarin causes warfarin embryopathy (nasal hypoplasia, stippled epiphyses) at 6 to 12 weeks gestation. Women with thrombotic APS planning pregnancy should switch to therapeutic LMWH preconception or by 6 weeks gestation, continued throughout pregnancy and 6 weeks postpartum, then resume warfarin.
SLE-APS overlap
30 to 40 percent of SLE patients have aPL antibodies, and approximately 10 to 15 percent of SLE patients meet APS clinical criteria. Hydroxychloroquine 200 to 400 mg daily is mandatory in all SLE patients regardless of APS status; it reduces lupus flares and reduces thrombotic risk in aPL carriers. Statin therapy is reasonable for cardiovascular prevention. Anticoagulation follows the same APS principles. Manage active lupus flares with cyclophosphamide, azathioprine, mycophenolate mofetil, or belimumab; avoid estrogen.
APS nephropathy
APS nephropathy is a small-vessel thrombotic microangiopathy of the renal cortex producing acute or chronic kidney injury, hypertension, and proteinuria. Biopsy shows focal cortical atrophy, fibrous intimal hyperplasia, fibrous and recanalized arterial thrombi, and TMA. Treatment is anticoagulation plus aggressive blood pressure control with ACE inhibitor or ARB; severe TMA may benefit from plasma exchange or eculizumab.
Surgical prophylaxis and bridging
Periprocedural management of APS patients on chronic warfarin requires careful planning. Stop warfarin 5 days preprocedure, bridge with therapeutic LMWH (enoxaparin 1 mg/kg SC q12h), hold last LMWH dose 24 hours preprocedure, resume LMWH 24 hours postoperatively, and resume warfarin postoperatively day 1 with continued LMWH until INR is therapeutic. Do not interrupt anticoagulation entirely without bridging in any APS patient; the risk of catastrophic thrombosis or CAPS exceeds bleeding risk in nearly all situations.
Pediatric APS
Pediatric APS is rare but well-described, often presenting as ischemic stroke, deep vein thrombosis, or recurrent fetal loss in adolescents. Diagnostic criteria are the adult Sydney criteria. Management mirrors adult algorithms: warfarin INR 2 to 3 (or 3 to 4 for arterial), avoid DOACs, hydroxychloroquine if SLE-associated. Long-term consequences of warfarin in growing children must be balanced with thrombosis risk.
Long-term surveillance
Annual visits with CBC, complete metabolic panel, urinalysis, complement levels (C3, C4 — depressed in active SLE-APS), ANA / anti-dsDNA if SLE, and aPL titer monitoring (LA, aCL, anti-β2GPI). Echocardiography every 2 to 5 years to screen for Libman-Sacks vegetations and pulmonary hypertension. Bone density assessment if on chronic glucocorticoids. Cardiovascular risk modification (smoking cessation, BP control <130/80, statin therapy as indicated, weight management, exercise) is critical.
S7. Practice Insights: What Drives APS Management at the Bedside
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)APS punishes shortcuts in anticoagulation selection and rewards meticulous antibody risk stratification. The pivot points are triple-positive recognition (it dictates VKA over DOAC), recognizing catastrophic APS early (CAPS triggers triple therapy within hours), and pregnancy management that starts at the positive pregnancy test, not at first complication. Three things are worth tracking at every visit: INR stability over the past month, antibody titer trend annually, and any subtle vascular event (livedo, microthrombi, cognitive complaints) — because APS recurrence often presents subclinically before the next thrombosis hits.
What the Guideline Misses — Triple-Positive Dictates VKA
The TRAPS trial and subsequent meta-analyses showed rivaroxaban inferiority to warfarin in triple-positive APS — higher arterial thrombosis. In experienced practice every APS patient gets a triple-positive workup at diagnosis (LAC + aCL IgG/IgM + anti-β2GP1 IgG/IgM) and the result drives anticoagulation choice. Triple-positive = warfarin INR 2-3 lifelong, never DOAC. Single/double-positive can consider DOAC, but warfarin remains the default in arterial events regardless.
Patterns That Recur — CAPS Is a Time-Critical Diagnosis
Catastrophic APS (≥3 organ thromboses in 1 week with confirmed APS or laboratory criteria) carries 30-50% mortality even with treatment. In routine practice, any APS patient with rapidly worsening multi-organ ischemia gets empiric triple therapy: full-dose anticoagulation + IV methylprednisolone 1 g daily × 3 days + PLEX or IVIG. Histologic confirmation is not worth waiting for; the diagnosis is clinical-laboratory and the window is hours.
A Pregnancy APS Protocol
Obstetric APS gets aspirin 81 mg PO daily + prophylactic LMWH (enoxaparin 40 mg SC daily) from positive pregnancy test through 6 weeks postpartum. For thrombotic APS history during pregnancy, therapeutic LMWH (enoxaparin 1 mg/kg SC BID) replaces warfarin throughout. Warfarin is not resumed until 12 weeks postpartum if breastfeeding; many such patients stay on LMWH throughout breastfeeding for convenience.
A Bedside Heuristic — Hydroxychloroquine for SLE-Overlap APS
SLE overlap is common in APS. Hydroxychloroquine 5 mg/kg/day (max 400 mg) reduces thrombosis recurrence in SLE-APS in observational data and offers favorable safety in pregnancy. Adding HCQ to anticoagulation in any SLE-APS patient, regardless of disease activity, is the defensible default. The ophthalmologic surveillance cost is justified by the additive thrombotic risk reduction.
A Case Pattern Worth Recognizing — DOAC Failure in Triple-Positive APS
Consider a woman in her early 40s with a remote DVT started on rivaroxaban by her primary team, who presents 8 months later with an acute right MCA stroke. Workup reveals triple-positive APS (LAC, aCL IgG, anti-β2GP1 IgG all strongly positive), confirmed on repeat testing 12 weeks later. The correction is a transition from rivaroxaban to warfarin INR 2.5-3.5 (arterial event) with hydroxychloroquine 400 mg daily added. The generalizable point: APS workup BEFORE starting anticoagulation in any unprovoked thrombosis in a patient under 50 — and respect the TRAPS data. Triple-positive patients placed on a DOAC are the ones most worth finding before the next event.
Protocol Tweaks That Diverge From Standard Guidelines
- APS antibody panel (full triple) before any anticoagulation choice in unprovoked DVT/PE under 50. The 1-2 week delay for results is worth it. Starting DOAC empirically and then discovering triple-positive forces a transition that itself carries thrombotic risk. Bridging with LMWH while panel results pend avoids that.
- INR 2.5-3.5 for arterial events, 2.0-3.0 for venous; never DOAC for triple-positive regardless. The differentiated target matters. Recurrence rates drop meaningfully at the higher target in arterial APS. clinicians document this rationale explicitly because community providers sometimes "normalize" the target back to 2-3 without realizing the patient had an arterial event.
- CAPS triple therapy initiated empirically on clinical suspicion within 6 hours. Don't wait for full Sydney criteria. Full-dose UFH or LMWH + methylprednisolone 1 g IV × 3 days + PLEX (5 sessions q2d) OR IVIG 0.4 g/kg × 5 days. Rituximab 375 mg/m² weekly × 4 for refractory CAPS. Hesitation here costs lives.
- Hydroxychloroquine 5 mg/kg/day in every SLE-APS overlap, regardless of SLE activity. Off-label for primary APS thromboprophylaxis, so extrapolation should stay cautious and anchored to the signal data. The thrombosis recurrence reduction in SLE-APS is real, and withholding it from pure APS patients without a contraindication is hard to justify.
Frequently Asked Questions
- Psoriatic Arthritis: Diagnosis, CASPAR Criteria, and Treat-to-Target Therapy
- Dermatomyositis and Polymyositis: Diagnosis and Management
- Polymyalgia Rheumatica: Diagnosis, GCA Overlap, Glucocorticoid Therapy, and Steroid-Sparing Strategies
- Hypermobility Spectrum Disorder and hEDS: Diagnosis and Management
- Septic Arthritis: Diagnosis, Joint Aspiration, and Empiric Antibiotic Management
- Rheumatoid Arthritis — Diagnosis and Disease-Modifying Therapy